EP 1467731 A1 20041020 - 3-(IMIDAZOLYL)-2-ALKOXYPROPANOIC ACIDS AS TAFIA INHIBITORS
Title (en)
3-(IMIDAZOLYL)-2-ALKOXYPROPANOIC ACIDS AS TAFIA INHIBITORS
Title (de)
3-(IMIDAZOLYL)-2-ALKOXYPROPIONSÄURE ALS TAFIA INHIBITOREN
Title (fr)
ACIDES 3-(IMIDAZOLYL)-2-ALKOXYPROPANOIQUES SERVANT D'INHIBITEURS TAFIA
Publication
Application
Priority
- GB 0201389 A 20020122
- GB 0202027 A 20020129
- IB 0300060 W 20030110
Abstract (en)
[origin: WO03061652A1] Compounds according to formula (I) wherein n is 0-3, R1 is optionally substituted C1-6 alkyl, C2-6 alkenyl, or C2-6 alkynyl, Heterocycle, Aromatic heterocycle, Aryl or hydrogen and R2, R3, R4, R5, R6, R7, R8 and R9 are each independently selected from hydrogen and optionally substituted C 1-6 alkyl, or R5 and R8 are an alkylene chain, are novel. They are useful in the treatment of thrombotic conditions and other pathologies associated with fibrin deposition.
[origin: WO03061652A1] Compounds according to formula (I) wherein n is 0-3, R<sp>1</sp> is optionally substituted C<sb>1-6</sb> alkyl, C<sb>2-6</sb> alkenyl, or C<sb>2-6</sb> alkynyl, Heterocycle, Aromatic heterocycle, Aryl or hydrogen and R<sp>2</sp>, R<sp>3</sp>, R<sp>4</sp>, R<sp>5</sp>, R<sp>6</sp>, R<sp>7</sp>, R<sp>8</sp> and R<sp>9</sp> are each independently selected from hydrogen and optionally substituted C <sb>1-6</sb> alkyl, or R<sp>5</sp> and R<sp>8</sp> are an alkylene chain, are novel. They are useful in the treatment of thrombotic conditions and other pathologies associated with fibrin deposition.
IPC 1-7
A61K 31/4172; A61K 31/4174; A61K 31/4178; A61P 7/02; C07D 233/54; C07D 403/12
IPC 8 full level
C07D 233/64 (2006.01); A61K 31/4172 (2006.01); A61K 31/4178 (2006.01); A61K 31/4439 (2006.01); A61P 7/02 (2006.01); A61P 9/10 (2006.01); A61P 17/02 (2006.01); A61P 19/04 (2006.01); A61P 29/00 (2006.01); A61P 35/00 (2006.01); A61P 41/00 (2006.01); A61P 43/00 (2006.01); C07D 233/54 (2006.01); C07D 401/04 (2006.01); C07D 403/12 (2006.01)
IPC 8 main group level
CPC (source: EP KR)
A61P 7/02 (2017.12 - EP); A61P 9/00 (2017.12 - EP); A61P 9/10 (2017.12 - EP); A61P 17/02 (2017.12 - EP); A61P 19/04 (2017.12 - EP); A61P 25/00 (2017.12 - EP); A61P 29/00 (2017.12 - EP); A61P 35/00 (2017.12 - EP); A61P 41/00 (2017.12 - EP); A61P 43/00 (2017.12 - EP); C07D 233/54 (2013.01 - KR); C07D 233/64 (2013.01 - EP); C07D 401/04 (2013.01 - EP); C07D 403/12 (2013.01 - EP KR)
Citation (search report)
See references of WO 03061652A1
Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT SE SI SK TR
DOCDB simple family (publication)
WO 03061652 A1 20030731; WO 03061652 A8 20040910; AP 2004003084 A0 20040930; AR 038197 A1 20050105; BR 0307016 A 20041103; CA 2472238 A1 20030731; CN 1620291 A 20050525; EA 200400716 A1 20041230; EC SP045200 A 20040827; EP 1467731 A1 20041020; HR P20040659 A2 20041031; IL 162677 A0 20051120; IS 7310 A 20040614; JP 2005520811 A 20050714; KR 20040077775 A 20040906; MA 27167 A1 20050103; MX PA04006573 A 20041004; NO 20043457 L 20040819; OA 12756 A 20060703; PA 8563501 A1 20040831; PE 20030929 A1 20031105; PL 371487 A1 20050613; TN SN04121 A1 20060601; TW 200302094 A 20030801; UY 27615 A1 20030829
DOCDB simple family (application)
IB 0300060 W 20030110; AP 2004003084 A 20030110; AR P030100165 A 20030121; BR 0307016 A 20030110; CA 2472238 A 20030110; CN 03802599 A 20030110; EA 200400716 A 20030110; EC SP045200 A 20040722; EP 03700059 A 20030110; HR P20040659 A 20040719; IL 16267703 A 20030110; IS 7310 A 20040614; JP 2003561596 A 20030110; KR 20047011370 A 20030110; MA 27786 A 20040715; MX PA04006573 A 20030110; NO 20043457 A 20040819; OA 1200400190 A 20030110; PA 8563501 A 20030122; PE 2003000058 A 20030117; PL 37148703 A 20030110; TN SN04121 A 20040630; TW 92100889 A 20030116; UY 27615 A 20030120